UK markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
85.44-0.59 (-0.69%)
At close: 5:35PM CEST

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
http://www.sanofi.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees100,409

Key executives

NameTitlePayExercisedYear born
Mr. Paul HudsonCEO & Director2.03MN/A1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFON/AN/A1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingN/AN/AN/A
Mr. Bruno MénardChief Information officerN/AN/AN/A
Mr. George Grofik C.F.A., CPA, CFAHead of Investor RelationsN/AN/AN/A
Ms. Karen LinehanExec. VP of Legal Affairs & Gen. CounselN/AN/A1959
Mr. Dante BeccariaGlobal Compliance Officer & VPN/AN/AN/A
Mr. Josep CatllaHead of CommunicationsN/AN/AN/A
Mr. Pierre ChancelSr. VP of Global Diabetes and Sr. VP of Global MarketingN/AN/A1957
Ms. Natalie BickfordExec. VP & Chief People OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Corporate governance

Sanofi’s ISS governance QualityScore as of 6 October 2020 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.